New cocktail of drugs takes on tough pancreatic cancer

NCT ID NCT04999969

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial is testing a combination of two experimental drugs (AZD0171 and durvalumab) plus standard chemotherapy in 126 people with advanced pancreatic cancer. The goal is to see if the combo is safe and helps patients live longer. Participants must have metastatic disease and provide tumor samples for analysis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZD0171, durvalumab, gemcitabine, and nab-paclitaxel
What this could lead to: If successful, this combination could offer a new treatment option for advanced pancreatic cancer, potentially improving survival rates.
What could go wrong: This is an early phase II trial with only 126 participants, so results may not apply to all patients. The combination may cause significant side effects, and it is not yet known if it works better than standard care alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC SOLID TUMOURS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic adenocarcinoma pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED OR METASTATIC SOLID TUMOURS

Contacts and locations

Locations

Research Site

La Jolla, California, 92037, United States
Research Site

Los Angeles, California, 90025, United States
Research Site

Orange, California, 92868, United States
Research Site

Ventura, California, 93003, United States
Research Site

Atlanta, Georgia, 30318, United States
Research Site

Coeur d'Alene, Idaho, 83814, United States
Research Site

Boston, Massachusetts, 02114, United States
Research Site

Ann Arbor, Michigan, 48109, United States
Research Site

Grand Rapids, Michigan, 49503, United States
Research Site

Buffalo, New York, 14263, United States
Research Site

New York, New York, 10065, United States
Research Site

Portland, Oregon, 97239, United States
Research Site

San Antonio, Texas, 78229, United States
Research Site

Charlottesville, Virginia, 22908, United States
Research Site

Seattle, Washington, 98195, United States
Research Site

Madison, Wisconsin, 53792, United States
Research Site

Barrie, Ontario, L4M 6M2, Canada
Research Site

Toronto, Ontario, M4N 3M5, Canada
Research Site

Toronto, Ontario, M5G 2M9, Canada
Research Site

Seongnam-si, 13620, South Korea
Research Site

Seongnam-si, 463-712, South Korea
Research Site

Seoul, 03080, South Korea
Research Site

Seoul, 03722, South Korea
Research Site

Seoul, 05505, South Korea
Research Site

Seoul, 06351, South Korea
Research Site

Seoul, 06591, South Korea
Research Site

Badalona, 08916, Spain
Research Site

Barcelona, 08035, Spain
Research Site

Madrid, 28027, Spain
Research Site

Madrid, 28034, Spain
Research Site

Madrid, 28041, Spain
Research Site

Madrid, 28050, Spain
Research Site

Majadahonda, 28222, Spain
Research Site

Pamplona, 31008, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.